Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Executive Summary

Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.


Related Content

How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Sandoz Eyes Doubling Of Japan Business Despite Price Pressures
Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Biosimilar Name Debate Heats Up As USP Says Zarxio Doesn't Need Suffix
FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
Sandoz Tells FDA Unique Biosimilar Names OK… Sometimes
The Curious Case Of FDA, Zarxio’s Name And The USP Monograph
Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say
GPhA Resorts To Citizen Petition On Biosimilar Naming


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts